Company Focus

Sanofi

Latest Sanofi News

Phesi flags mounting risks for Phase III atopic dermatitis trials
Pharmaceutical
A new analysis from US data analytics firm Phesi has raised concerns about the viability of ongoing Phase III trials in atopic dermatitis (AD), pointing to a rising risk of failure driven by flawed trial design and overreliance on saturated investigator sites.   9 July 2025


Insights

Company Spotlight

Latest News & Features of interest to Sanofi

Latest Relevant Ones To Watch News


More in M&A >


Relevant Ones to Watch Companies

Reset all filters
Refine Search